Hosted on MSN

Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early

CEO Marianne De Backer highlighted the completion of enrollment in ECLIPSE 1, Vir’s first registrational Phase III study for hepatitis delta, ahead of internal projections. She indicated that "we now ...
Hosted on MSN

Vir Biotechnology doses first patient in Phase 1 part 3 trial of VIR-5500

Vir Biotechnology (VIR) “announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors.
Morningstar

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen ...

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for ...
Seeking Alpha

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab in a variety of EGFR-expressing solid tumors such ...